highlight clinical analysis of influence of met-enkephaThe effects of methionine enkephalin (met-enkepha-lin in volunteers and patients suffering from cancer or lin) on human immune function are reviewed. This AIDS.
INTRODUCTION
strain differences, which have been documented by Fischer (11) . Recent studies have shown that enkephalins and enMethionine enkephalin binds with high affinity for dorphins are produced by cells of the immune system the d receptors but low affinity to the m receptor, while during periods of antigen and/or mitogen activation of b-endorphin has high affinity for the m and epsilon rethe lymphocytes-the major specific reactive cells of ceptors and low affinity for the d receptor. These differthe immune system (1) . Various peptide fragments de-ences in receptor affinities may account for differences rived from the prohormones, proopiomelanocortin, and in immunological influences reported for methionine proenkephalin A have been studied and described (2) , enkephalin and b-endorphin (3, 4, (11) (12) (13) . Indeed, Maand substantial literature documents the immunomod-zumder et al. (14) have recently reported d opioid recepulatory influences of these fragments, particularly b-tor-selective peptides to have marked immunostimuendorphin, methionine enkephalin, and leucine en-lant activities in both normal persons and patients kephalin (3) . Each of these peptides has been reported suffering from leprosy and tuberculosis while m recepto induce immunostimulation at low doses and immu-tor-selective peptides appear to act immunodepressive nosuppression at high doses in the majority of donor in the same subjects. samples (4) . Similar biphasic responses have been reported for a variety of cytokines such as interleukin 2
ORIGIN OF ENKEPHALINS
and several interferons (5) . This review is designed to focus on the immunological influences of methionine The enkephalins were originally described as the enenkephalin (met-enkephalin) on human cells and to dogenous ligands for morphine receptors in the brain (15). Plotnikoff et al. showed that the enkephalins ex- 1 Dr. Murgo coauthored this paper in his private capacity.
hibit antidepressant, antianxiety, and anticonvulsant activities (16). Enkephalins are normally produced in receptors from which agonists are displaced by very low doses of naloxone are not involved (8, 42) . adrenal glands as well as in the hypothalamus (17). In a normal healthy state, enkephalins are released in a Methionine enkephalin, b-endorphin, and ACTH have been found in homogenates of bone marrow cells 6:1 ratio of methionine enkephalin to leucine enkephalin, into the adrenal venous plasma (18). In 1979, Wy-of leukemic children (43) . Proenkephalin A activity has been found in human chronic lymphoblastic leukemia bran et al. (19) reported that normal human T lymphocytes possess receptors for methionine enkephalin, and cells (44) . The enkephalins have been shown to have high affinity for the d receptor (2) . In light of this it is subsequently the presence of opiate receptors on human phagocytic leukocytes was reported (20) . Recent surprising that methionine and leucine enkephalin have been reported to have major differences in their studies have shown that human peripheral blood lymphocytes contain proenkephalin A messenger RNA and effects on immune cell activity. Miller et al. (37) reported that methionine enkephalin increases rosette release endorphins and proenkephalin A-derived peptides including methionine enkephalin (21, 22). Similar formation of T cells in lymphoma patients over a wide dilution range (10 02 to 10 014 M) whereas leucine enfindings have been reported in rats and mice (23-25). Studies with human peripheral blood lymphocytes sug-kephalin enhanced only at one dilution (10 014 M). Similarly Roscetti et al. (45) reported that methionine engest that phytohemagglutinin mitogen stimulation of lymphocytes provokes release of methionine enkepha-kephalin had a biphasic influence on blastogenesis induced by Candida antigen, causing stimulation in eight lin peptides (1, 2, 22, (26) (27) (28) (29) (30) that methionine enkephalin increased sheep red blood cell rosetting of lymphocytes in normal subjects and Methionine enkephalin causes increases in interleualso in some patients with lymphoma (35) (36) (37) . Direct kin 2 production when human peripheral blood monobinding of naloxone to human lymphocytes and plate-nuclear cells are incubated with PHA and methionine lets has been reported by Mehrishi and Mills (38). Addi-enkephalin at concentrations between 10 09 and 10 06 M tionally, leucine enkephalin has been shown to bind to (40) . Similarly, interferon gamma production in concacultured T lymphocytes of a human lymphoid T cell navalin A-stimulated human mononuclear cells was inline (Jurkat) (39) . Wybran and Schandene (40) demon-creased by both b-endorphin and methionine enkephastrated that methionine enkephalin increased expres-lin, at concentrations between 10 014 and 10 010 M (48). sion of (CD 2) OKT10, Leu 11 (CD 16), and TAC surface Naloxone did not prevent this effect, indicating that antigens (CD 25) on leukocytes. This increase was also this influence represents a nonopioid effect (48). shown to be reversed by treatment with naloxone. Finally, human granulocytes and monocytes have been
ENKEPHALIN INFLUENCES MITOGEN-INDUCED PROLIFERATION OF LYMPHOID CELLS
shown to express high-affinity binding to dihydromorphine and naloxone but not to 3H-D-Ala-D-Leu-enkephalin (20, 41) . Most in vitro studies have shown a biphasic effect of the opioids on phytomitogen stimulation of immune Of significance are reports of Hucklebridge et al. (42) that methionine enkephalin stimulates in vitro prolif-cells. Low doses of opioids tend to enhance proliferative responses to phytomitogens while high doses tend to eration, in the absence of other mitogens, of human peripheral blood lymphocytes after an incubation pe-act as suppressors of these same responses. In our own analyses we observed differences in phytomitogen reriod of 4 to 5 days. This stimulation appears to occur via d opioid receptors. This stimulation of lymphocytes sponses to opioids that appeared to be a function of mitogen concentration, low vs moderate vs high mitoby metenkephalin is antagonized by high but not by low concentrations of naloxone, indicating that the m gen levels. Perhaps high mitogen levels result in a ceil-ing effect that exerts a negative feedback influence,
In vivo studies. Intravenous treatment of normal volunteers and cancer and AIDS patients with methioresulting in inhibition of T cell proliferation (bimodal effects -bell shaped curve)? It is often difficult to com-nine enkephalin (20 to 100 mg/kg) increased blastogenesis of lymphocytes exposed to suboptimal and optimal pare findings between laboratories because many reported studies used only a single concentration of phy-concentrations of PHA, Con A, and pokeweed mitogen in 70 to 80% of the subjects tested (54, 55). The in vivo tomitogen and these concentrations often vary among laboratories. Threshold changes may be more physio-physiological concentrations of methionine enkephalin achieved which influenced the responses of immune logical and therefore the use of suboptimal mitogen concentrations may be the most informative way of cells normally ranged from 10 010 to 10 012 M. Biphasic responses of methionine enkephalin to phytomitogens looking at this relationship. Another problem with comparing studies from different laboratories is that the in vitro have been observed over wide concentration ranges. Methionine enkephalin is found in human blood reported culture time of immune cells in the presence of mitogen has ranged from 72 hr to 7 days. Recognizing in a picogram (10 012 M) range (56). Therefore, differences seen between in vitro and in vivo may be a funcall of these difficulties, we still think it worthwhile to review the reported influence of opioids on mitogen tion of the concentrations of methionine enkephalin employed, as well as influences of optimal vs suboptimal stimulation of immune cells while recognizing that inconsistencies may exist.
mitogen concentrations, and duration of incubation of the cells with the enkephalins and/or phytomitogens. In vitro studies. Wybran (34) In contrast to these findings, Prete et al. (51) reported that methionine enkephalin exerted no influence on that methionine enkephalin diminished NK cell activ-PHA-induced blastogenesis of immune cells from nor-ity at target to effector cell ratios of 200:1 when the mal subjects but depressed the response in cells from cells were incubated for 6 to 72 hr in the presence of uremic patients (52). Antibody synthesis to tetanus tox-IL2. Kastin et al. (63) could not produce significant oid was inhibited by methionine enkephalin at low con-effects of met-enkephalin on NK cell activity when cells centrations and increased by high levels of methionine from healthy subjects ranging in age from 23 to 79
were treated with methionine enkephalin. The great enkephalin (53) (bimodal response
human PMNs. may result from methodological differences or differences in the subjects analyzed; for example, target to These studies taken together indicate that methionine enkephalin induces biphasic responses over a effector ratios as well as incubation times.
broad range of dose concentrations and that these effects may be influenced by incubation times and the
ENKEPHALIN EFFECTS ON GRANULOCYTES AND MONOCYTES
age of the subject from which the cells are taken. The majority of reports indicates that methionine enkephalin increases PMN activities as exhibited by increased Foris et al. (64) (65) . In a subsequent study methionine to delta receptors in the brain but not in the immune enkephalin was shown to increase the intracellular system. killing capability of human PMNs (as did f-Met-LeuMethionine enkephalin stimulates the adherence of Phe-FMLP following a 30-min incubation) (66) . The auhuman neutrophils to serum protein-coated slides (75) . showed that methionine enkephalin increases prostowere incubated with methionine enkephalin for periods cyclin production and thus may dampen immune-trigof 10 to 30 min the production of superoxide was engered, granulocyte-induced endothelial damage. Perezhanced in cells from individuals with low baselines Castrillon et al. (77) speculate that the functional dewhile it was suppressed in cells from individuals with fect in chemotactic response of monocytes obtained high baselines. However, Simpkins et al. (68) reported from intravenous drug abusers may be due to a recepthat leucine enkephalin and methionine enkephalin intor effect (downregulation) or could be attributed to a hibit superoxide release by human phagocytic cells folnonspecific action on the monocytes. They showed a lowing 15 to 30 min incubation of the cells with the decrease in chemotactic function in monocytes from neuropeptide. Slaoui-Hasnaoui et al. (69) studied the control subjects when these cells were treated with the effects of leucine enkephalin, b-endorphin, and dynorselective m and d receptor agonists DAGO and DPDPE, phin on the respiratory burst of human PMNs. They suggesting that the response is receptor mediated and found that none of the tested opioid peptides affected that the opioids play an important role in the depresresting oxidative metabolism in the PMNs. However, sion of monocyte chemotaxis that may be observed in the opioid peptides suppressed a phorbol myristate aceintravenous drug abusers. Methionine enkephalin intate (PMA)-stimulated respiratory burst in a bellduction of adherence, conformational changes, and loshaped dose response of the PMNs. Conversely, if the comotor activity in human granulocytic cells have been opioid peptides were first exposed to activated oxygen confirmed by the studies of Stefano et al. (78) . It is species, they enhanced the PMA-stimulated respirainteresting to note that enkephalin analogs may have tory burst in human PMNs in an inverted U-shaped different affinities for d receptors, again suggesting the dose response. Peck found that superoxide production evidence of specific receptors with different influences was not increased in macrophages following 3 days of on the function of immune cells. incubation with methionine enkephalin (70) . Superox- 
Cancer patients. Patients with Kaposis sarcoma (9 tered to 14 normal volunteers by intravenous infusion patients), lung cancer (12 patients), melanoma (3 paas a single dose delivered over a 30-min period in dose tients), hypernephroma (1 patient), or pancreatic canranges of 1 to 250 mg/kg (54, (79) (80) (81) (82) (83) (84) (85) . This treatment cer (1 patient) were treated with methionine enkephawith methionine enkephalin was found to increase the lin for varying periods of time (1 week to 12 months) number of cells in T cell subsets (CD 4, CD 8, and CD over a wide range of doses (10 mg/kg 31/week up to 2 cells), enhance proliferation induced by the mitogen 80 mg/kg 31/week) (82-84, 86-92). Increases in T cell PHA, ConA, and pokeweed mitogen, and increase numsubsets were observed after 1 to 2 weeks of treatment. bers of T cell rosettes, total circulating lymphocytes, B
The T cell subsets influenced included CD 3, CD 4, lymphocytes, and NK cells. Subjects with low baseline CD8, and CD 2 positive cells. Increases in blastogenic NK cell activity exhibited increased NK cell activity responses to PHA, ConA, and pokeweed mitogen were following methionine enkephalin treatment while observed. A major finding was an increase in interleuthose with high baseline activities exhibited a slight kin 2 receptor expression. NK cell activity was meadecrease in NK cell function. No major signs of toxicity sured in 14 of these patients and an increased NK acwere observed, including no changes in cardiovascular tivity was present in 12 of the 14 patients. No toxicity or respiratory activity or alteration of body temperaattributable to the molecule was observed in any of ture.
these patients (85, 86, 88, 90, 99) . A variety of normal and malignant human lympho-AIDS patients. Clinical studies in AIDS patients poietic and nonlymphopoietic cells express a membrane were conducted at five centers (Tulsa, Brussels, Denantigen with functional enkephalinase activity (100 ver, New York, and Chicago) (6, (82) (83) (84) (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) (97) (98) . The and 101). This membrane-associated enkephalinase, patients in these studies were HIV-infected persons which has also been called common acute lymphoblaswho could be classified as pre-AIDS or patients suffertic leukemia antigen, CD10, melalloendopeptidase, EC ing from ARC (AIDS-related complex). Treatment with 3.4.24.11, and neutral endopeptidase, hydrolyses enmethionine enkephalin ranged in dosage from 10 mg/ kephalins and multiple other bioactive peptides. It is kg 31/week up to 100 mg/kg 31/week in the first month conceivable that one mechanism of downregulating the of treatment. Succeeding months of treatment often immunomodulatory effects of enkephalin is accelerated included a schedule of treatment infusion of 100 mg/kg degradation of the peptide in a microenvironment conof methionine enkephalin once a week. A dose response taining normal or malignant cells expressing high levwas apparent, which included minimal influence on T els of enkephalinase. cell subsets observed in the Denver study at a fixed dose of 10 mg/kg 31/week for 12 weeks, to significant DISCUSSION AND CONCLUSIONS increases in T cells at 20 to 80 mg/kg 31/week for 1 to 6 months at Brussels and Tulsa. Increases in CD 3, CD 4, and CD 8 T cell subsets, NK cell activity, IL2
As indicated in this review ample evidence exists production, and blastogenic response to PHA stimula-that enkephalins may exert immunomodulatory inflution were observed in 70 to 80% of the patients studied. ences. While biphasic responses have been demonIncreases of T cell subsets were seen to be sustained strated, it is clear that at physiologic concentrations for periods of 1 to 19 months of treatment, most pa-(10 010 and 10 012 M) the enkephalins are capable genertients being treated for 3 to 6 months. No significant ally of exerting immunoenhancing actions in the majortoxicity was observed in any of these patients. ity of subjects. Most reports indicate that the enkephaThe most recent clinical study with methionine en-lins have a high affinity for d-like subreceptors on imkephalin was conducted by Bihari and colleagues (55) mune cells. However, it is also clear that these d who studied the influence of two doses of methionine subreceptors differ from those found in the central nerenkephalin (60 or 125 mg/kg) once a week in 46 ARC vous system because known d ligands have different patients over a 12-week placebo controlled trial. No affinities for receptors in the brain and immune system. significant toxicity was observed in any of the patients. The receptor on immune cells may vary not only in kind The high-dose group (125 mg/kg/week) exhibited a sig-and number among individuals but also as a function of nificant increase in IL2 receptors, CD56 (NK) cell num-species, strain, age, disease state, sex, and ''set points'' bers, blastogenic response to stimulation with PHA, of activation. It is very difficult to compare results from pokeweed mitogen, or CMV, CD3, CD4, and CD8 posi-different laboratories because of the great diversity of tive T cell numbers, and a significant reduction in total conditions employed in the reported studies (i.e., differences in the enkephalin doses, differences in exposure lymph node size after 8 and/or 12 weeks of treatment.
reappraisal of the role of the various opioid receptor subtypes in times, differences in the subject populations studied, cell-mediated immunity. Neuroimmunology 1, 141-147, 1994. etc. rosettes. Of great interest is the fact that treatment 741, 1-38, 1994. with methionine enkephalin has led to increased pro- We believe that methionine enkephalin may best be 18. Hanbauer, I., Kelly, G. D., Saiani, L., and Yang, H. Y. T., [Met
